共 75 条
[1]
Boyle P(2005)Cancer incidence and mortality in Europe, 2004 Ann Oncol 16 481-488
[2]
Ferlay J(1993)Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37-41
[3]
Murad AM(1995)Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591
[4]
Santiago FF(1997)Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163-168
[5]
Petroianu A(2003)S-1 in gastric cancer: a comprehensive review Gastric Cancer 6 2-8
[6]
Pyrhonen S(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-1720
[7]
Kuitunen T(2000)Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191-197
[8]
Nyandoto P(2003)Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) Eur J Cancer 39 1264-1270
[9]
Glimelius B(1998)An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416-419
[10]
Ekstrom K(2001)Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133-1137